GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » Cyclically Adjusted PB Ratio

SBFM (Sunshine Biopharma) Cyclically Adjusted PB Ratio : 0.00 (As of May. 31, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma Cyclically Adjusted PB Ratio?

As of today (2025-05-31), Sunshine Biopharma's current share price is $1.43. Sunshine Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was $819.60. Sunshine Biopharma's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Sunshine Biopharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Sunshine Biopharma's highest Cyclically Adjusted PB Ratio was 13.62. The lowest was 0.01. And the median was 1.08.

SBFM's Cyclically Adjusted PB Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.88
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Sunshine Biopharma's adjusted book value per share data for the three months ended in Mar. 2025 was $8.379. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $819.60 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sunshine Biopharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Sunshine Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Cyclically Adjusted PB Ratio Chart

Sunshine Biopharma Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 1.73 0.54 -

Sunshine Biopharma Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.01 - - -

Competitive Comparison of Sunshine Biopharma's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Biopharma's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sunshine Biopharma's Cyclically Adjusted PB Ratio falls into.


;
;

Sunshine Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sunshine Biopharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.43/819.60
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Sunshine Biopharma's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=8.379/134.9266*134.9266
=8.379

Current CPI (Mar. 2025) = 134.9266.

Sunshine Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.000 99.792 0.000
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.000 101.863 0.000
201703 0.000 102.862 0.000
201706 0.000 103.349 0.000
201709 0.000 104.136 0.000
201712 0.000 104.011 0.000
201803 0.000 105.290 0.000
201806 0.000 106.317 0.000
201809 0.000 106.507 0.000
201812 0.000 105.998 0.000
201903 0.000 107.251 0.000
201906 0.000 108.070 0.000
201909 0.000 108.329 0.000
201912 0.000 108.420 0.000
202003 0.000 108.902 0.000
202006 -711.000 108.767 -882.000
202009 -655.000 109.815 -804.781
202012 -1,055.000 109.897 -1,295.284
202103 -1,184.000 111.754 -1,429.502
202106 -973.000 114.631 -1,145.267
202109 -1,274.000 115.734 -1,485.268
202112 112.000 117.630 128.469
202203 3,328.250 121.301 3,702.108
202206 4,653.889 125.017 5,022.792
202209 4,487.000 125.227 4,834.565
202212 1,966.091 125.222 2,118.465
202303 1,766.182 127.348 1,871.292
202306 1,777.615 128.729 1,863.202
202309 1,689.385 129.860 1,755.305
202312 1,514.714 129.419 1,579.170
202403 496.140 131.776 508.001
202406 20.049 132.554 20.408
202409 12.513 133.029 12.692
202412 9.104 133.157 9.225
202503 8.379 134.927 8.379

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sunshine Biopharma  (NAS:SBFM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sunshine Biopharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Biopharma Business Description

Traded in Other Exchanges
N/A
Address
333 Las Olas Way, CU4 Suite 433, Fort Lauderdale, FL, USA, 33301
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
Executives
Camille Sebaaly director, officer: CFO and Secretary 14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun 10 percent owner 1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller director 10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey director 6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish director 6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah director 924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp 10 percent owner 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty director, 10 percent owner, officer: CEO and President 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki director, officer: Chief Operating Officer 731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di director, officer: Chief Operating Officer 3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3